ArticleCirculation research2018
Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?
Article in Circulation research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Diagnostic Value of Three-Dimensional Speckle Tracking Imaging Strain Parameters for Detection of Cancer Chemotherapy-Related Cardiac Dysfunction: A Meta-Analysis.Arquivos brasileiros de cardiologia · 2023Pooled it
- Cardiovascular adverse events associated with cyclophosphamide, pegylated liposomal doxorubicin, vincristine, and prednisone with or without rituximab ((R)-CDOP) in non-Hodgkin's lymphoma: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin.Cancer medicine · 2021Trial
- Early cardiac proteomic profiling in a long-latency doxorubicin cardiomyopathy model exhibits sexual dimorphism for cardioprotection.Journal of molecular and cellular cardiology plus · 2026Article
- Safety and Treatment Efficacy of Systemic, Locoregional, and Nanoparticle Encapsulated Anthracycline Chemotherapy: Insights Into Cardiotoxicity.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- CARDIOVASCULAR COMPLICATIONS OF CHEMOTHERAPY IN BREAST CANCER: A SCOPING REVIEW.Annals of Ibadan postgraduate medicine · 2026Article
- Natural bioactive molecules and chemotherapeutics synergism for enhanced cancer therapy.Nutrition & metabolism · 2026Review
- Cardio-Oncology and Breast Cancer Therapies.Current treatment options in oncology · 2025Review
- Article
- Roles of Non-Coding RNA in Anthracycline Cardiotoxicity: A Narrative Review.Journal of inflammation research · 2025Review
- Pleiotropic Multi-Drug Co-Assembled Nanocomposites Offer Protection Against Doxorubicin-Induced Cardiotoxicity.International journal of nanomedicine · 2025Article
- Preventive effect of imperatorin against doxorubicin-induced cardiotoxicity through suppression of NLRP3 inflammasome activation.Journal of natural medicines · 2025Article
- Navigating cancer therapy induced cardiotoxicity: From pathophysiology to treatment innovations.Advanced drug delivery reviews · 2024Review
- AI-assisted mass spectrometry imaging withChemical science · 2024Article
- Exploring the effects of calycosin on anthracycline-induced cardiotoxicity: a network pharmacology, molecular docking, and experimental study.Frontiers in cardiovascular medicine · 2024Article
- The diagnostic value of global longitudinal strain combined with cardiac biomarkers on early detection of anthracycline-related cardiac dysfunction.Journal of echocardiography · 2023Article
- NLRP3-mediated inflammation in cardio-oncology: sterile yet harmful.Translational research : the journal of laboratory and clinical medicine · 2023Review
- Exploration of the Use of Natural Compounds in Combination with Chemotherapy Drugs for Tumor Treatment.Molecules (Basel, Switzerland) · 2023Review
- Anthracycline-induced cardiotoxicity: mechanisms, monitoring, and prevention.Frontiers in cardiovascular medicine · 2023Review
- Cardio-Oncology Rehabilitation-Present and Future Perspectives.Life (Basel, Switzerland) · 2022Review
Corrections and comments
- Commented on by
- Commented on by
- Comment on
Authors and funding
1 author.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.